Indivior Pharmaceuticals, Inc. London S.E.

Equities

INDV

US45579U1097

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		-.--%	-

01-26	Indivior Pharmaceuticals Completes Redomiciliation to US From UK	MT
01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI

Transcript : Indivior PLC, Q1 2025 Earnings Call, Apr 24, 2025

Published on 04/24/2025 at 08:00 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Indivior PLC Q1 2025 Financial Results Conference Call. [Operator Instructions] Please be

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Indivior Pharmaceuticals, Inc.

01-26	Indivior Pharmaceuticals Completes Redomiciliation to US From UK	MT
01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI
01-08	Indivior Expects Up to $1.20 Billion in 2026 Net Revenue	MT
01-08	(INDV) Indivior Expects 2026 Revenue Range $1.13B - $1.2B, vs. FactSet Est of $1.19B	MT
12-22	Indivior Joins S&P SmallCap 600 Index	MT
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 1000	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Pharmaceuticals Select Industry Index	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600 Health Care	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Composite 1500	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600	CI
11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI
25-10-30	Sector Update: Health Care Stocks Rise Late Afternoon	MT
25-10-30	Indivior PLC, Q3 2025 Earnings Call, Oct 30, 2025
25-10-30	Top Midday Gainers	MT
25-10-30	Indivior PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Indivior Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Outlook Raised - Shares Up Pre-Bell	MT
25-10-30	Indivior PLC Raises Earnings Guidance for the Year 2025	CI
25-10-30	Earnings Flash (INDV) Indivior PLC Reports Q3 Revenue $314.0M, vs. FactSet Est of $261.9M	MT
25-10-30	Earnings Flash (INDV) Indivior PLC Posts Q3 Adjusted EPS $0.72 per Share, vs. FactSet Est of $0.41	MT
25-10-15	Indivior Says Rapid Sublocade Induction Improves Retention in Opioid Use Disorder Trial	MT
25-10-15	Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open	CI
25-10-01	UK's Indivior to re-domicile to US after listing move	RE
25-10-01	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation	CI
25-09-21	Indivior PLC(NasdaqGS:INDV) added to S&P TMI Index	CI